Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.390 -0.020 (-0.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased ↗
The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Looking Into Cabaletta Bio's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Cabaletta Bio's Recent Short Interest ↗
 
Via Benzinga
News headline image
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire
News headline image
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
From Cabaletta Bio
Via GlobeNewswire
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode ↗
U.S. stock futures advanced on Friday after a day's break for Thanksgiving as investors look to end November on a high note. 
Via Benzinga
News headline image
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial ↗
 
Via Benzinga
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
News headline image
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024 ↗
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges ↗
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
News headline image
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.